Related references
Note: Only part of the references are listed.Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior
Thuy Nguyen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure-Activity Relationship, and Molecular Modeling Studies
Dongliang Guan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist
Guangyao Lin et al.
MOLECULES (2021)
Development of Relaxin-3 Agonists and Antagonists Based on Grafted Disulfide-Stabilized Scaffolds
Han Siean Lee et al.
FRONTIERS IN CHEMISTRY (2020)
Effects of C-Terminal B-Chain Modifications in a Relaxin 3 Agonist Analogue
Praveen Praveen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of a small molecule RXFP3/4 agonist that increases food intake in rats upon acute central administration
Brian DeChristopher et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Central relaxin-3 receptor (RXFP3) activation impairs social recognition and modulates ERK-phosphorylation in specific GABAergic amygdala neurons
Hector Albert-Gasco et al.
BRAIN STRUCTURE & FUNCTION (2019)
Single chain peptide agonists of relaxin receptors
Praveen Praveen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2019)
Differential effects of relaxin-3 and a selective relaxin-3 receptor agonist on food and water intake and hypothalamic neuronal activity in rats
Camila de Avila et al.
BEHAVIOURAL BRAIN RESEARCH (2018)
TCFH-NMI: Direct Access to N-Acyl Imidazoliums for Challenging Amide Bond Formations
Gregory L. Beutner et al.
ORGANIC LETTERS (2018)
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Terry Kenakin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Central relaxin-3 receptor (RXFP3) activation increases ERK phosphorylation in septal cholinergic neurons and impairs spatial working memory
Hector Albert-Gasco et al.
BRAIN STRUCTURE & FUNCTION (2017)
Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain
Sherie Ma et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders
Jigna Rajesh Kumar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Development of a Single-Chain Peptide Agonist of the Relaxin-3 Receptor Using Hydrocarbon Stapling
Keiko Hojo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Hydrocarbon stapled B chain analogues of relaxin-3 retain biological activity
Tharindunee Jayakody et al.
PEPTIDES (2016)
Synthesis and pharmacological characterization of a europium-labelled single-chain antagonist for binding studies of the relaxin-3 receptor RXFP3
Linda M. Haugaard-Kedstroem et al.
AMINO ACIDS (2015)
Relaxin-3 Receptor (RXFP3) Signalling Mediates Stress-Related Alcohol Preference in Mice
Andrew W. Walker et al.
PLOS ONE (2015)
Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides
Daniel Conole et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Signalling profiles of H3 relaxin, H2 relaxin and R3(B.23-27) R/I5 acting at the relaxin family peptide receptor 3 (RXFP3)
M. Kocan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Relaxin-3 mRNA levels in nucleus incertus correlate with alcohol and sucrose intake in rats
P. J. Ryan et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure-Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)
Nadezhda German et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Relaxin-3 is associated with metabolic syndrome and its component traits in women
Maivel H. Ghattas et al.
CLINICAL BIOCHEMISTRY (2013)
Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus
D. E. Ganella et al.
GENE THERAPY (2013)
RELAXIN FAMILY PEPTIDES AND THEIR RECEPTORS
R. A. D. Bathgate et al.
PHYSIOLOGICAL REVIEWS (2013)
Relaxin-3/RXFP3 system regulates alcohol-seeking
Philip J. Ryan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Key Agonist-induced Conformational Change in the Cannabinoid Receptor CB1 Is Blocked by the Allosteric Ligand Org 27569
Jonathan F. Fay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Minimization of Human Relaxin-3 Leading to High-Affinity Analogues with Increased Selectivity for Relaxin-Family Peptide 3 Receptor (RXFP3) over RXFP1
Fazel Shabanpoor et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics
Janet Munro et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency
Lily Alvarez-Jaimes et al.
PLOS ONE (2012)
Design, Synthesis, and Characterization of a Single-Chain Peptide Antagonist for the Relaxin-3 Receptor RXFP3
Linda M. Haugaard-Kedstrom et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Relaxin family peptide systems and the central nervous system
G. E. Callander et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
R3(BΔ23-27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7 -: In vitro and in vivo characterization
Chester Kuei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction
Scott G. Summerfield et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism
Emma T. van der Westhuizen et al.
MOLECULAR PHARMACOLOGY (2007)
Structure-brain exposure relationships
Stephen A. Hitchcock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: Further support that relaxin-3 is the physiological ligand for GPCR135
Steven W. Sutton et al.
NEUROENDOCRINOLOGY (2005)
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier
Q Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7
CL Liu et al.
MOLECULAR PHARMACOLOGY (2005)
Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species
JC Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135
CL Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of relaxin-3/INSL7 as a ligand for GPCR142
CL Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2
S Sudo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
KMM Doan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Share Paper
